li001

Ovarian Cancer Found to Hijack Healthy Cells to Speed Deadly Spread

Research Advances /

A new study explains why ovarian cancer spreads so quickly and becomes so dangerous. Researchers found that cancer cells do not spread alone. Instead, they recruit healthy cells in the abdomen to help them invade other organs. Unlike many cancers that travel through the bloodstream, ovarian cancer cells float in abdominal fluid. During this time, […]

Ovarian Cancer Found to Hijack Healthy Cells to Speed Deadly Spread Read More »

Study Shows Strong Results for Keytruda Combination Before Surgery in Head and Neck Cancer

Treatment /

A phase 2 study found that combining pembrolizumab (Keytruda) with docetaxel and cisplatin before surgery works very well for patients with locally advanced head and neck squamous cell carcinoma that can still be removed. In the study of 49 patients, 87.8% responded to treatment. Among those who had surgery, 44.4% had no remaining cancer found

Study Shows Strong Results for Keytruda Combination Before Surgery in Head and Neck Cancer Read More »

EI24 Gene Shows Dual Role in Cancer, Emerging as Promising Diagnostic and Therapeutic Target

Molecular Oncology /

New research highlights the complex role of the EI24 gene in cancer, showing that it can act either as a tumor suppressor or, in some cases, support tumor growth. EI24 is activated by the p53 tumor suppressor when DNA is damaged and plays a key role in autophagy and programmed cell death—two processes that help

EI24 Gene Shows Dual Role in Cancer, Emerging as Promising Diagnostic and Therapeutic Target Read More »

CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Survival and Safety With Cilta-Cel

Research Advances /

The CARTITUDE-4 trial shows that how well patients respond to bridging therapy — treatment given while waiting for CAR T-cell manufacturing — strongly affects how well cilta-cel (Carvykti) works in relapsed or refractory multiple myeloma. Patients whose disease improved or stayed stable during this waiting period had much better survival and fewer serious side effects

CARTITUDE-4 Analysis Shows Bridging Therapy Response Predicts Survival and Safety With Cilta-Cel Read More »

New mRNA Technology Targets Cancer Cells While Sparing Healthy Tissue

Molecular Oncology /

Researchers have developed a new platform called the Cancer-Selective modRNA Translation System (cSMRTS), which allows mRNA therapies to work only in cancer cells while avoiding healthy tissue. The system uses a dual mRNA “on/off” circuit based on microRNA patterns. In healthy cells, a sensor mRNA blocks the treatment. In cancer cells, tumor-specific microRNAs disable the

New mRNA Technology Targets Cancer Cells While Sparing Healthy Tissue Read More »

Final MOUNTAINEER Results Confirm Durable Benefit of Tucatinib–Trastuzumab in HER2-Positive Metastatic Colorectal Cancer

Treatment /

The final results of the Phase 2 MOUNTAINEER trial confirm that the combination of tucatinib (Tukysa) and trastuzumab (Herceptin) provides lasting benefit with manageable side effects for patients with HER2-positive, RAS wild-type metastatic colorectal cancer. After a median follow-up of 32.4 months, the confirmed overall response rate was 39.3%. Median overall survival reached 23.9 months,

Final MOUNTAINEER Results Confirm Durable Benefit of Tucatinib–Trastuzumab in HER2-Positive Metastatic Colorectal Cancer Read More »

EMA Recommends Retifanlimab Plus Chemotherapy as New First-Line Option for Advanced Anal Cancer

News /

The European Medicines Agency (EMA) has recommended approval of retifanlimab (Zynyz) combined with carboplatin and paclitaxel as a first-line treatment for adults with metastatic or inoperable recurrent squamous cell carcinoma of the anal canal. The recommendation is based on results from the phase 3 POD1UM-303 trial. Patients who received retifanlimab plus chemotherapy had better outcomes

EMA Recommends Retifanlimab Plus Chemotherapy as New First-Line Option for Advanced Anal Cancer Read More »

New Study Identifies Molecular Switch Driving Aggressive Pancreatic Cancer

Molecular Oncology /

Researchers have identified a key molecular switch that controls how aggressive pancreatic ductal adenocarcinoma becomes and how it responds to treatment. The study shows that mutant KRAS, the main driver of pancreatic cancer, suppresses GATA6, a gene that helps cancer cells stay more mature and treatment-responsive. When GATA6 is turned off, tumors shift into a

New Study Identifies Molecular Switch Driving Aggressive Pancreatic Cancer Read More »

Lower Starting Dose of Padcev Combo Improves Tolerability Without Reducing Survival, Study Finds

Treatment /

A new study found that starting patients on a lower dose of enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) can improve tolerability without reducing survival in advanced urothelial carcinoma. Researchers analyzed data from 496 patients treated with this first-line combination and compared standard dosing with lower starting doses. Patients who began at a reduced dose had fewer

Lower Starting Dose of Padcev Combo Improves Tolerability Without Reducing Survival, Study Finds Read More »

FDA Grants Fast Track Status to Pelareorep for KRAS-Mutant Metastatic Colorectal Cancer

Drug Approvals /

The FDA has given Fast Track designation to pelareorep (Reolysin), an intravenous oncolytic virus therapy, for second-line treatment of patients with KRAS-mutant, microsatellite-stable metastatic colorectal cancer. The therapy is used in combination with standard treatment, bevacizumab plus FOLFIRI. The decision is based on Phase 1 trial data showing strong improvements compared with historical standard care.

FDA Grants Fast Track Status to Pelareorep for KRAS-Mutant Metastatic Colorectal Cancer Read More »